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Introduction: Genes involved in testicular differentiation, spermatogenesis, proliferation and apoptosis of germ cells
have been shown to evolve rapidly and display rapid DNA changes. These genes are therefore good candidates for
explaining impairments in spermatogenesis. Initial studies of some of these genes appear to confirm this
hypothesis. The RHOXF2 candidate gene belongs to the RHOX family clustered in Xq24 and is specifically expressed
in the testis. It contains four exons and codes for a 288 amino acid (aa) transcription factor. It has a high degree of
homology (>99.9%) with its paralogue RHOXF2B, which is also preferentially expressed in the testis.
Objectives: To sequence RHOXF2 and RHOXF2B in intracytoplasmic sperm injection (ICSI) patients and identify any
single-nucleotide polymorphisms (SNPs) associated with impaired spermatogenesis.
Materials: A cohort of 327 patients in ICSI programmes at Poissy and Bichat hospitals. All patients gave their
written, informed consent to participation. One hundred patients had unaffected spermatogenesis and 227
displayed impaired spermatogenesis.
Methods: The four exons in each of RHOXF2 and RHOXF2B were sequenced in 47 patients with oligospermia or
non-obstructive azoospermia. Given that exons 2 and 3 were found to harbour most of the SNPs, only these two
exons were sequenced in the remaining 280 subjects.
Results: Due to the extremely high degree of sequence identity between RHOXF2 and RHOXF2B, we were not able
to distinguish between the sequences of these two genes. Although 9 SNPs were identified, there were no
significant frequency differences between ICSI patients with normal vs. impaired spermatogenesis. Two insertions
were identified: a 21-nucleotide insertion was retrieved in both groups and a guanine insertion (inducing a
premature stop codon) only found in two patients with impaired spermatogenesis.
Conclusion/outlook: RHOXF2 is a good candidate for rapid evolution by positive selection. Analysis of the
polymorphism frequency in exons 2 and 3 did not allow us to correlate the identified SNPs with male infertility.
However, a single nucleotide insertion was identified only in men with impaired spermatogenesis. Further work will
be needed to establish whether genetic changes in RHOXF2 can give rise to defects in spermatogenesis.
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Introduction: Les gènes impliqués dans la différenciation des testicules, la spermatogenèse, la prolifération et
l'apoptose des cellules germinales ont été montrés comme ayant une évolution rapide de la séquence d’ADN. Ces
gènes sont donc de bons candidats pour expliquer les déficiences de la spermatogenèse. Les premières études
semblent confirmer cette hypothèse. Le gène RHOXF2, appartenant à la famille des gènes RHOX avec un cluster
dans Xq24, est un bon candidat car spécifiquement exprimé dans les testicules. Ce gène a un degré élevé
d’homologie (> 99,9%), avec son paralogue RHOXF2B , qui est également exprimé préférentiellement dans
les testicules.
Objectifs: Séquencer RHOXF2 chez des patients infertiles bénéficiant d’une injection intracytoplasmique de
spermatozoïdes (ICSI) afin d’identifier des polymorphismes associés à une déficience de la spermatogenèse.
Matériels: Une cohorte de 327 patients inclus dans un programme d’ICSI. Tous les patients ont donné leur
consentement écrit et éclairé à la participation de cette étude. Cent patients n’avaient pas d’altération de la
spermatogenèse et 227 avaient une déficience.
Méthodes: Les quatre exons de RHOXF2 ont été séquencés chez 47 patients présentant une oligospermie ou une
azoospermie non obstructive. Étant donné que les exons 2 et 3 ont été trouvés comme ayant le plus de SNPs, seuls
ces deux exons ont été séquencés dans les 280 sujets restants.
Résultats: Bien que 9 SNPs aient été identifiés, il n’y avait pas de différence de fréquences significatives entre les
patients ayant une altération, ou non de la spermatogenèse. Deux insertions ont été identifiées: une insertion de 21
nucléotides retrouvées dans les deux groupes et une insertion d’une guanine (induisant un codon stop prématuré)
chez deux patients présentant une altération de la spermatogenèse.
Conclusion: RHOXF2 est un bon candidat pour une évolution rapide par sélection positive. L’analyse de la
fréquence des polymorphismes dans les exons 2 et 3 ne nous permet pas actuellement de corréler les SNP
identifiés avec l’infertilité masculine. Cependant, une insertion d’un seul nucléotide a été identifiée uniquement
chez des hommes avec une déficience de la spermatogenèse. Des travaux complémentaires seront nécessaires
pour déterminer l'impact du gène RHOXF2 sur la spermatogenèse.
Keywords: RHOXF2, Pression de selection positive, Infertilité, Cluster de gènes, HoméodomaineIntroduction
The study of genetic divergence between humans and
chimpanzees [1] revealed the existence of certain groups
of rapidly evolving genes subject to positive selection. This
translates into a relatively high frequency of nucleotide se-
quence changes and then amino acid substitutions. More
recently, studies of human single nucleotide polymor-
phisms (SNPs) have shown that some human genes have
evolved in response to positive selection pressure [2]. This
mechanism seems to preferentially affect genes involved
in gametogenesis, apoptosis and immunity. Of these can-
didate genes, RHOXF2, USP-26, Spo-11 and PRM1 and
PRM2 are involved in different stages of spermatogenesis,
NROB1 and REα are involved in testicular differentiation,
and HYAL3 and TSARG1 are involved in the prolifera-
tion/apoptosis of germ cells. Due to the presence of a large
number of genes involved in the mechanisms of gameto-
genesis, it has been suggested that at least some of them
have a role in infertility. Nielsen [1] hypothesized that mu-
tations that increase cell proliferation and decrease germ
cell apoptosis can sometimes be detrimental for the devel-
opment of other parts of the body and may thus be subject
to genomic conflict. This phenomenon might be partlyresponsible for the positive selection of these genes. Stud-
ies comparing infertile men with impaired spermatogen-
esis (oligospermia or azoospermic of secretory origin) with
a control population of patients with normal spermato-
genesis have already been undertaken. The preliminary re-
sults appear to confirm the involvement of genes such as
USP26 [3], PRM1, PRM2 [4-6], TNP1, TNP2 [7], Spo11
[8,9] and REα [10] in impaired spermatogenesis. Using a
candidate gene approach, we chose to study the RHOXF2
gene (also known as PEPP-2 for Pem, Esx1, Psx1, PSx2).
RHOXF2 is a member of the RHOX family of genes lo-
cated in Xq24. It features a the Pem DNA homeobox se-
quence encoding a 60 amino acid (aa) homeodomain
protein that interacts with DNA. The protein is expressed
in Sertoli cells [11,12] and is involved in germ cell devel-
opment in mice [11-13]. The RHOX gene family forms
a cluster on the X chromosome in humans (RHOXF1,
RHOXF2 and RHOXF2B) (Figure 1) and in mice (compris-
ing 12 genes). This family is characterized by two introns
that are always located at the same point within the home-
odomain. RHOXF2 has four exons and encodes a tran-
scription factor that is specifically expressed in the testis.
Although the transcription factor’s role is not known in
Figure 1 RHOX genes. A. Human RHOX cluster. B. Mouse RHOX
cluster (from Mc Lean et al. [13]). C. Human RHOXF1 and RHOXF2
(from Wayne et al. [12]).
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RHOXF2) is involved in sperm maturation [13]. It encodes
a 288 amino acids protein with a high glutamic acid N-
terminal domain and a proline-rich domain in the C
terminal [14]. When comparing the human and Pan trog-
lodytes chimpanzee RHOXF2 sequences, 21 differences
have been described: 3 in exon 1, 8 in exon 2, 2 in exon 3and 7 in exon 4. In human exon 2, there is also a 21 bp
(CAG CAGAAC CCC GTC ACC GCC) insertion at nu-
cleotide 322. In humans, the RHOXF2 and RHOXF2B
paralogues have a very high degree of sequence homology
(>99.9%) but has the opposite orientation on the X
chromosome. The currently known differences between
the two genes are an adenine-thymine substitution at
codon 93 and a thymine-cytosine substitution at codon
131 [14]. To date, few polymorphisms have been described
for this gene [14]. More recently, [15], a study of RHOXF2
copy number in primates showed that duplication only oc-
curred in humans and four Old World monkey species
(with at least 6 copies in chimpanzees). Furthermore, there
was evidence of on-going selection for RHOXF2. Recently,
it has been shown that the RHOXF2/2B genes are select-
ively expressed in the testis - primarily in germ cells in the
adult testis but also in prespermatogonia in the human
foetal testis. RHOXF2/2B mRNA expression increases in
the second trimester during the development of the foetal
testes (when gonocytes differentiate into prespermato-
gonia) [16]. The objective of the present study was to test
for the involvement of RHOXF2 genes in male infertility
of secretory origin. To this end, we implemented a two-
step strategy. In order to confirm the presence of new se-
quence variants, we first sequenced the RHOXF2/2B genes
in a group of patients with impaired spermatogenesis. We
then compared cases and controls in terms of the fre-
quency of the newly identified SNPs.
Material and methods
Population (Table 1): We sequenced RHOXF2 in 327 pri-
mary infertility patients participating in in vitro fertilization
(IVF) programmes at Poissy and Bichat hospitals. The pa-
tients were divided into two groups as a function of the al-
teration in spermatogenesis (Table 1). Group 1 comprised
patients with normal sperm characteristics (according to
the WHO criteria [17]; sperm count >39 × 106/ejaculate or
>15 × 106/ml) participating in an intracytoplasmic sperm
injection (ICSI) program for conventional IVF failures
(Group 1a, n = 73) and patients with obstructive azoosper-
mia and normal spermatogenesis (Group 1b, n = 27). All
group 1b patients had a normal testicular volume, urinary
tract abnormalities (as confirmed by clinical and ultrasound
examinations), alterations in at least one semen biochemis-
try parameter and normal testicular histology. Group 2 com-
prised patients with oligospermia (sperm count <39 × 106/
ejaculate or <15 x 106/ml) (group 2a, n = 168) or non-
obstructive azoospermia (Group 2b, n = 59). All azoosper-
mic patients had altered testicular histology, normal semen
markers, low testicular volume (volume < 10 ml) and no
chronic pelvic inflammatory disease (i.e. a negative semen
culture and fewer than 1 × 106 round cells per ejaculate).
Infertile patients had undergone extensive assessment,
including family and personal medical histories, physical
Table 1 Patients’ testicular and hormonal parameters
Groups 1: Normal spermatogenesis 2: Altered spermatogenesis
Settings a: Control b: Obstructive azoospermia a: Oligospermia b: Non obstructive azoospermia
Patients number 73 27 167 60
Semen Volume (ml) 4.1* ± 1.7** 2.8 ± 2.2 3.6 ± 1.8 3.5 ± 1.4
Sperm count (M/ml) 68.8 ± 61.7 / 2.7 ± 3.6 /
Motility (a + b) (%) 54.2 ± 10.4 / 22.9 ± 16.4 /
Normal form (%) 43.2 ± 10.4 / 11.9 ± 11.3 /
FSH (UI/l) 5.0 ± 3.9 3.9 ± 1.9 11.9 ± 8.5 21.2 ± 13.5
LH (UI/l) 3.3 ± 1.4 3.2 ± 1.4 5.7 ± 3.1 7.5 ± 4.7
Total testosterone (ng/ml) 4.8 ± 2.3 4.8 ± 1.7 4.5 ± 1.8 4.0 ± 1.5
Inhibine B (pg/ml) 172.5 ± 69.0 158.4 ± 79.0 81.2 ± 60.1 33.3 ± 47.3
*mean; **standard deviation.
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tion analysis. Testicular histology parameters and semen
biochemical parameters (L-carnitine, fructose and citric
acid) were analyzed in azoospermic patients. Sperm param-
eters were evaluated according to standard criteria (WHO,
1999). The hormone profile (FSH, LH, inhibin B and total
testosterone) was determined in all groups of patients. All
patients had a normal blood karyotype and no chromosome
Y microdeletions. All participants gave their written, in-
formed consent to participation in the study (which had
been approved by an independent ethics committee CPP
Ile de France XI) during pre-IVF genetic counselling.
The major exclusion criteria were as follows: age >50,
vasectomy, endocrine disorders (hypogonadotropic hypo-
gonadism), hormone therapy, toxic habits (>40 cigarettes
per day, alcohol abuse and/or drug abuse), immunosup-
pressive treatment, chemotherapy and/or radiotherapy,
unilateral orchidectomy, abnormal karyotype, Y chromo-
some deletions and chronic genital tract infections.
In order to identify potential polymorphisms and muta-
tions, we initially sequenced all four RHOXF2 exons in
47 patients with oligospermia or non-obstructive azoo-
spermia (i.e. from groups 2a and 2b). We then sequenced
exons 2 and 3 in the remaining 280 participants. All gen-
etic variations were compared with the 1000 Genomes
(http://browser.1000genomes.org/Homo_sapiens) and Ex-
ome Variant Server (EVS) (http://evs.gs.washington.edu/
EVS/) databases.
Genomic DNA was extracted from blood samples
using the Wizard® GenomicDNA Purification kit (Promega,
Southampton, UK).
Primer design
The primer pairs for each of the four exons were selected
using Oligo software (Molecular Biology Insights, Inc.
Cascade, CO, USA). The forward and reverse primer se-
quences consisted of 21 to 30 nucleotides and were se-
lected 25–30 nucleotides upstream and downstream ofthe exons (with a minimum number of G/Cs, in order to
prevent dimer formation) (Table 2).
DNA amplification
PCRs were performed on 1 μl of native DNA with Taq
Gold ®, 3 μl 25 mM MgCl2, and 1 μl 5 mM dNTP. A total
of 35 cycles were performed (denaturation at 96°C for
30 s; hybridisation at 60°C for 30 s (exons 1 and 2) or 57°C
for 30 s (exons 3 and 4); elongation at 72°C for 60 s). The
PCR fragments were then purified enzymatically with Exo-
SAP (USB, Cleveland, Ohio, USA).
DNA sequencing
DNA was sequenced using 1 μl Big Dye Terminator on an
Eppendorf thermocycler with the following program: hot
start: 96°C for 5 min; 25 cycles (denaturation at 96°C for
30 s, hybridization at 50°C for 15 s, elongation at 60°C for
4 min); final elongation: 60°C, 10 min. After purification
on a Sephadex G50 plate Millipore column, raw sequences
were analyzed and interpreted with Seqscape® software
(Applied Biosystems, Life Biotechnologies, NY, USA).
Statistical analysis
Intergroup comparisons of polymorphism and haplotype
frequencies were performed with Fisher’s exact test and
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cance was set to p < 0.05. All analyses were performed
with Statview software (SAS Institute Inc., Cary, NC,
USA).
Results (Table 3)
First, all four RHOXF2 exons were sequenced in 47 pa-
tients with oligospermia or non-obstructive azoospermia.
The sequences corresponded to RHOXF2. In view of the
high degree of sequence homology (>99.9%), a pseudo-
biallelic nomenclature was adopted for the SNPs’ geno-
type. Five previously described heterozygous SNPs [14]
were identified: 3 on exon 2, one on exon 3 and one on
exon 4. These SNPs were also present in the 1000 Ge-
nomes and EVS databases. A previously described frame-
shift variant in exon 2 (a guanine insertion leading to a
premature stop codon (TGA) of the cDNA (c.381dupG).p.
(L128Afs*34)) was also identified. Given that we did not
find any new SNPs in exons 1 and 4, we decided to only
study exons 2 and 3 in the remaining 280 patients. The
overall study population therefore comprised 100 patients
from group I and 227 patients from group II. We identi-
fied five heterozygous SNPs (all located in exon 2) in our
population. Three had been reported previously and two
had not. One of the latter was a 21-nucleotide duplication
(GAG AAG AAA AAG ATG GCG GCGGCC) from nu-
cleotide 246 onwards; this leads to a 7 aa protein duplica-
tion (QKKKMAA) at aa 82 and thus a 295 aa protein).
This duplication (official nomenclature: c.225_245dup,p.
(Glu76_Gly82dup)) was found in one patient from group I
and three patients from group II. A c.381dupG was
found in one patients with impaired spermatogenesis.
Overall, four SNPs were synonymous and five wereTable 3 Exons 2 and 3 SNPs frequencies
SNP and DNA change Previously describe
(Included in the homeodomain)
c.202G > A rs148604152
c.225_245dup, No
c.267A > G rs149340601
c.277G > A all rs146311958
Homozygote
c.381dupG Yes no rs
c.381C > T No
c.396C > T rs199940228
c.411C > T rs142963365
c.451C > T no
c.452G > A all rs142899626
Homozygote
c.526C > T rs199871532non-synonymous. Furthermore, two insertions (one of
which led to a premature stop codon) were identified
only in patients with spermatogenesis failure. There
were no intergroup differences in SNP frequency
(Table 3) and no haplotype differences were observed
when combining the three most frequent SNPs
(p.D93N, R151H and p.L176F). Three patients were homo-
zygous for D93N and one was homozygous for R151H.
Sperm characteristics were for the two oligospermic
patients with the c.381dupG as follow : Patient 1: sperm
count: 2.20 x106/ml, motility: 38%, typical form: 0%; Pa-
tient 2: sperm count: 4/ml, .motility and typical form not
performed.
Considering all subgroups separately (Additional file 1:
Table S1), the only significant frequency difference was
observed for p.D93N (the most frequent SNP, found in
74.2% of the study population) comparing azoospermic
(73.8%) and oligospermic patients (88.1%) with spermato-
genesis failure (p = 0.0288).
Discussion
Genetic divergence between Homo sapiens and the
chimpanzee may result from positive selection pressure
(notably on genes involved in immunity, gametogenesis
and apoptosis) [1,2]. The positive selection pressure on
male gametogenesis is higher in humans than in the
chimpanzee [18]. Rapid evolution of these genes leads to
changes in one or more nucleotides, which in turn can
impair the function of the corresponding protein and, in
some cases, cause infertility. In humans, the X and Y
chromosomes are particularly exposed to this selection
pressure because of the absence of Y homologous re-
combination during meiosis and low recombinationd Variant type genetic Group 1 Group 2 p(I vs II)=
Variation at protein level (n = 100) (n = 227)
n (%) n (%)
Missense p.G68R 1(1.0) 1(0.4) 0.5188
p.Glu76_Gly82dup 1 (1.0) 3 (1.3) 1
Synonymous p.L89= 2 (2.0) 0 0.0929
Missense p.D93N 75 (75.0) 176 (77.5) 0.6703
1 (1.0) 2 (0.9) 1
Frameshift p.L128Afs*34 0 2 (0.9) 0.8617
Synonymous p.G127= 0 1 (0.4) 1
Synonymous p.A133= 0 1 (0.4) 1
Synonymous p.N137= 0 1 (0.4) 1
Missense p.R151C 0 2 (0.9) 1
Missense p.R151H 40 (40.0) 98 (43.2) 0.6281
0 1 (0.4) 1
Missense p.L176F 10 (10.0) 17 (7.5) 0.5136
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shown that male infertility can be related to Y chromo-
some defects [19-23]. One can therefore hypothesize
that male infertility can be caused by polymorphisms in
X chromosome genes involved in spermatogenesis. Mu-
tations in the USP26 gene in Xq28 (also considered to
be subject to positive selection pressure) were found in
7% of a series of patients with Sertoli cell-only syndrome
[24]. The fact that other X chromosome polymorphisms
(both SNPs [25] and copy number variations [26]) have
been recently reported strengthens the hypothesis whereby
they have an impact on spermatogenesis. The RHOX fam-
ily gene is located in Xq24 and codes for transcription fac-
tors that are only expressed in the testes. Mice have 12
RHOX orthologues, which are also organised in a cluster
[12,13]. Some of these genes are only partially duplicated
[27,28]. Of these, Rhox5 is expressed in Sertoli cells and
appears to have an important role in spermatogenesis.
Impaired expression leads to azoo-teratospermia and in-
creased apoptosis of germ cells. Humans RHOXF2 pre-
sents a high degree of sequence homology (63.8%) with
the mouse Rhox5 gene [12]. Few RHOXF2 polymorphisms
have been identified and there are no data on their fre-
quency. In humans, the RHOXF2 and RHOXF2B paralo-
gues have a very high degree of sequence homology
(>99.9%). RHOXF2B is located less than 100 kb away from
RHOXF2 but has the opposite orientation. The human
gene duplication is thought to have occurred very recently
[14]. Due to the very high degree of homology (99.9%),
there are no data on the differential expression of these
two paralogues. A recent study of sequence and copy
number variations of RHOXF2 in humans and a non-
human primates showed a parallel gene duplications/
losses in multiple primate lineages [15]. Eleven non-
human primate species have only one RHOXF2 copy, two
copies are present in humans and four Old World species
of monkey and at least six copies are present in chimpan-
zees. The gene duplication in primates was probably medi-
ated by non-allelic recombination via flanking endogenous
retroviral sequences [15]. Furthermore, an analysis of eight
non-synonymous variant sites in humans has suggested
that the gene selection process is on-going. Furthermore,
it was recently reported that RHOXF2B is selectively
expressed in male germ cells [16]. These various datasets
support the hypothesis whereby RHOXF2 variants may be
present in patients with impaired spermatogenesis. Our
two-step strategy (based on the preliminary identification
of new variants in a small group of patients with impaired
spermatogenesis and then extension of the analysis to con-
trol patients) enabled us to identify (i) new synonymous
and missense variants and (ii) two frame-shift variants
(one of which was associated with a premature stop
codon). However, patients with and without impaired
spermatogenesis did not differ in terms of the frequencyof these polymorphisms. We established haplotypes on
the basis of the three most frequent polymorphisms but
again did not observe any differences in frequency be-
tween the two groups of patients. These findings suggest
that there is no correlation between the frequency of
RHOXF2 polymorphisms and impaired spermatogenesis.
However, this result is preliminary because our study only
covered RHOXF2′s coding sequences. It would be inter-
esting to study the promoter regions in patients with im-
paired spermatogenesis. The RHOXF2 promoter has a
high degree of homology with that of the mouse Rhox5
gene [12], which contains an androgen binding site. The
presence of polymorphisms in this region could therefore
modulate RHOXF2 transcription and reduce translation.
In the mouse, low Rhox5 expression was shown to have a
harmful effect on spermatogenesis [13]. Furthermore, we
did not study exon 4, which carries a polymorphism that
is defined as harmful by the PANTHER classification sys-
tem (http://www.pantherdb.org). We identified two rare
duplications in our patients with impaired spermatogen-
esis. The first duplication is a guanine insertion that shifts
the reading frame, induces a premature stop codon and
thus produces a truncated protein. This duplication was
found in two patients with spermatogenesis failure and
none of the control patients. The EVS database lists this
duplication for only one individual, the fertility of which is
not stated. Given that Rhox gene mutation alter testicular
function in rodents [27], this variant may indeed be patho-
genic. The second duplication is located in exon 2. This is
a duplication of a 21-bp fragment from base 165, resulting
in the insertion of a 7 aa polypeptide (but no change in
the homeodomain). This mutation was identified in three
patients with impaired spermatogenesis and in one control
patient.
Except for the frameshift mutation p.L128Afs*34 which
disrupts the homeodomain (from amino acid 134 to 193),
the others SNPs do not exhibit a specific phenotype. This
may be due to several aspects. Firstly, seven of the 11 re-
ported SNPs were outside the homoeodomain. Secondly,
one of the remaining four SNPs is synonymous. For 2 of
the others, the substituted amino acid is quite similar to
the native amino acid and thus does not induce a great
change in homeodomain’s conformation (the basic amino
acid arginine and histidine for p.R151H and the non-polar
leucine and phenylalanine amino acids for p.L176F). The
most interesting variation is probably p.R151C, in which
arginine is replaced by the dissimilar cysteine. A change in
the homeodomain’s interaction with DNA cannot there-
fore be ruled out. When compared with the two previ-
ously mentioned SNPs, p.R151C was only observed in the
group of patients with spermatogenesis failure. However,
the very low frequency explains the absence of a statisti-
cally significant difference (as was is also the case for the
frameshift mutation p.L128Afs*34). Thirdly, the amino
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orthologues [12]. Hence, these various points may explain
why negative results were observed in our series and, in
particular, why the RHOXF2 SNPs did not appear to pre-
dispose their bearers to infertility.Due to technical limita-
tions and the very high degree of homology between
RHOXF2 and RHOXF2B, we could not distinguish be-
tween RHOXF2 or RHOXF2B polymorphisms. It is not yet
known whether the two paralogues have distinct functions
or complement each other perfectly. It is therefore impos-
sible to determine the relative impact of the different poly-
morphisms or duplications on spermatogenesis. In order
to confirm our present results, it would be interesting to
sequence exon 2 in a larger cohort of patients and con-
trols. An analysis of RHOXF2 and RHOXF2B expression
patterns would also be very interesting but would require
us to be distinguish between the two paralogues.Conclusion
Mutations in the RHOXF2 and RHOXF2B genes (which
encode homeodomain proteins exclusively expressed in
the testis) might explain some cases of male infertility.
Our study confirmed the presence of the polymorphisms
identified by Wayne [14] and a number of new polymor-
phisms. A truncating mutation (caused by insertion of a
nucleotide) was encountered only in patients with im-
paired spermatogenesis. Although several polymorphisms
were identified in RHOXF2 and RHOXF2B (suggesting re-
cent positive selection pressure), there were no significant
difference between patients with impaired spermatogen-
esis and control patients in terms of the polymorphism
frequencies. It would nevertheless be interesting to (i) con-
tinue this analysis of RHOXF2 and RHOXF2B in a larger
population, (ii) sequence exon 4 and the promoter se-
quence and (ii) study other testis-active genes located on
chromosome X, (such as PEPP-1 (OTEX) [14,29], ESX1-R
[30], ESX-1 L [31,32], TGIFL-X [33]) or genes that have
been subjected to positive selection pressure. If possible,
specific analysis of RHOXF2 and RHOXF2B expression
should tell us whether both genes are expressed exclu-
sively in the testis and which of the two paralogues is re-
quired for spermatogenesis.Additional file
Additional file 1: Table S1. Exons 2 and 3 SNPs frequencies in all
subgroups.
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